Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2261 for refractory chronic cough (Phase II, randomized, double-blind, placebo-controlled)
CTR20230367Phase 2Completed
- Sponsor
- Chengdu Shengdi
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-2261 in refractory chronic cough (RCC), chronic idiopathic cough (CIC), sponsored by Chengdu Shengdi. Started Mar 2023; status: completed.
02
Drugs
HRS-2261
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on CTR20230367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230367.